Mapping the MIF-2 Chemokine Interactome Reveals MIF-2-CCL20 Complex Formation in Liver Fibrosis

This study identifies and characterizes a novel MIF-2/CCL20 complex in liver fibrosis, demonstrating that their interaction inhibits MIF-2's tautomerase activity and modulates immune and stromal responses to potentially regulate disease progression.

The Gist

The Big Picture: A Traffic Jam in the Liver

Imagine your liver is a busy city. When the city gets injured (like from too much fat or alcohol), it sends out emergency sirens to call for help. These sirens are proteins called chemokines. Their job is to recruit "repair crews" (immune cells) to fix the damage.

Usually, the city knows when to stop the sirens once the repair is done. But in liver fibrosis (scarring), the sirens keep blaring, and the repair crews keep arriving, piling up so much that they accidentally build a wall of scar tissue instead of fixing the problem.

This study discovered a new "traffic cop" system that tries to calm things down, but it works in a very surprising way.

---

The Main Characters

1. MIF-2 (The New Dispatcher):
   Think of MIF-2 as a new, powerful emergency dispatcher. It's been around for a while, but scientists just realized how important it is in the liver. It usually shouts, "Come here, everyone!" to attract immune cells to the injury site.

2. CCL20 (The Old Siren):
   This is an older, well-known emergency signal. It also shouts, "Come here!" specifically to a certain type of repair crew (T-cells). In a healthy liver, it's quiet. But in a scarred (fibrotic) liver, it's screaming loudly.

3. The "Handshake" (The Complex):
   The big discovery of this paper is that MIF-2 and CCL20 don't just shout at the same time; they actually grab onto each other.

   • The Analogy: Imagine MIF-2 and CCL20 are two people shouting directions at a crowd. Usually, they shout in harmony, sending everyone to the same spot. But in this study, the researchers found that MIF-2 and CCL20 decided to hold hands and form a single unit.
   • The Result: When they hold hands, they stop shouting. Instead of calling the repair crews to the site, they effectively mute the alarm.

---

How They Found It (The Detective Work)

The scientists acted like detectives trying to figure out who MIF-2 was friends with.

1. The Speed Dating Event (Protein Array): They put MIF-2 in a room with 47 different "suspects" (other proteins). They saw which ones MIF-2 liked to hang out with. CCL20 was one of the top favorites.
2. The Handshake Test (SPR & MST): They used high-tech machines to measure how tightly MIF-2 and CCL20 held hands. The answer: Very tightly. They stick together like Velcro.
3. The Blueprint (Computer Modeling): They used a super-smart AI (AlphaFold) to build a 3D model of what this "handshake" looks like. It turns out CCL20 fits right into a specific pocket on MIF-2, like a key in a lock. This fit is so tight that it actually stops MIF-2 from doing its other job (a chemical reaction called tautomerase activity).
4. The Real-World Check (Human Liver Tissue): They looked at actual liver samples from patients. They found that in livers with heavy scarring (fibrosis), MIF-2 and CCL20 were found holding hands much more often than in healthy livers.

---

What Does This "Handshake" Actually Do?

The researchers wanted to know: Does holding hands change the message?

Experiment 1: The T-Cell Taxi Service

• Scenario: They put immune cells (CD4+ T-cells) in a gel that mimics liver tissue.
• Test A: They shouted "MIF-2!" The cells rushed toward the sound.
• Test B: They shouted "CCL20!" The cells didn't move much (because they didn't have the right "ears" to hear it well).
• Test C: They shouted both at the same time (the complex).
• Result: The cells stopped moving. The MIF-2/CCL20 handshake acted like a "Do Not Disturb" sign. It neutralized the call for help.

Experiment 2: The Factory Workers (Fibroblasts)

• Scenario: They looked at fibroblasts (the cells that build scar tissue).
• Test: They exposed these cells to MIF-2 alone or CCL20 alone. The cells started producing IL-6, a chemical that causes inflammation and more scarring.
• Result: When they exposed the cells to the MIF-2/CCL20 complex, the production of IL-6 dropped significantly. The handshake calmed the factory workers down.

---

Why This Matters (The Takeaway)

For a long time, scientists thought that in liver disease, you just needed to block the "bad" signals to stop scarring. But this study suggests the body has its own internal braking system.

• The Problem: In liver fibrosis, the body is overwhelmed with signals to repair, leading to too much scarring.
• The Discovery: The body tries to fix this by pairing MIF-2 with CCL20. This pairing creates a "complex" that dampens the noise. It stops the immune cells from rushing in and stops the scar-builders from getting too excited.
• The Future: This is a double-edged sword. Sometimes this "braking system" might be too weak to stop the scarring, or maybe it's trying to stop the repair too early. Understanding exactly how MIF-2 and CCL20 hold hands could help doctors design new drugs. Maybe we can create a drug that forces them to hold hands tighter to stop the scarring, or breaks their grip if we need the immune system to fight an infection.

In short: The liver has a secret "mute button" made of two proteins holding hands. When they clasp, they silence the alarm, potentially slowing down the formation of scar tissue. This paper is the first map of how that mute button works.

Technical Summary

1. Problem Statement

Chronic inflammation that fails to resolve often leads to organ fibrosis, a pathological state characterized by excessive extracellular matrix deposition. While chemokines are known initiators of inflammation, their network complexity—including the formation of heterocomplexes between classical chemokines (CKs) and atypical chemokines (ACKs)—remains poorly understood.

• Specific Gap: Macrophage Migration-Inhibitory Factor (MIF) is a well-studied ACK. Its structural homolog, MIF-2 (D-DT), is an independent inflammatory modulator with high basal expression in the liver. However, the MIF-2 chemokine interactome (specifically its ability to form heterocomplexes with CKs) had not been systematically mapped.
• Clinical Context: Liver fibrosis (e.g., in NAFLD/NASH) involves complex immune-stromal crosstalk. Identifying specific protein-protein interactions that modulate this process could reveal new therapeutic targets.

2. Methodology

The study employed a multi-disciplinary approach combining high-throughput screening, biophysical validation, structural modeling, and functional assays using human tissues and cells.

• High-Throughput Screening:
  • Chemokine Protein Array: A comprehensive array containing 47 human chemokines (all subfamilies: CC, CXC, CX3C, XC) and selected DAMPs/ACKs was probed with biotinylated MIF-2 at pH 8.0 to identify binding partners.
• Biophysical Validation:
  • Surface Plasmon Resonance (SPR): Used to validate array hits and determine binding affinities ($K_D$) of MIF-2 with candidate chemokines.
  • Microscale Thermophoresis (MST): Performed in solution to confirm MIF-2/CCL20 complex formation independently.
  • Peptide Array: Overlapping 15-mer peptides covering the CCL20 sequence were used to map the specific binding interface on CCL20.
  • Tautomerase Activity Assay: A fluorometric assay measured MIF-2's enzymatic activity in the presence of CCL20 to test for functional inhibition.
• Structural Modeling:
  • AlphaFold 3.0: Used to generate in silico heterodimer models of the MIF-2/CCL20 complex to visualize spatial relationships and predict interface residues.
• Human Tissue Analysis:
  • RNA-Seq Re-analysis: Bulk RNA-sequencing data (GSE135251, n=206) from human liver biopsies (NAFL to NASH/F4) were re-analyzed to assess expression patterns of MIF-2, CCL20, and their receptors.
  • Protein Analysis: Western blotting, semi-endogenous pull-down assays (using recombinant His-tagged CCL20), and Proximity Ligation Assay (PLA) on human liver cryosections (fibrotic vs. non-fibrotic) to detect in situ complex formation.
• Functional Assays:
  • 3D Chemotaxis: Live-cell tracking of primary human CD4⁺ T cells in a collagen matrix to assess migration toward MIF-2, CCL20, or the complex.
  • Fibroblast Activation: Primary human dermal fibroblasts were stimulated to measure IL-6 secretion (a marker of inflammation and fibroblast activation) under single vs. combined chemokine stimulation.

3. Key Contributions

• Mapping the MIF-2 Interactome: The study is the first to systematically define the MIF-2 chemokine interactome, revealing a broader spectrum of binding partners than previously known for MIF.
• Discovery of MIF-2/CCL20 Complex: Identified CCL20 (MIP-3$\alpha$) as a high-affinity binding partner of MIF-2.
• Structural Insight: Provided a structural model showing the C-terminus of CCL20 docking into the tautomerase pocket of MIF-2, a site critical for MIF-2 function and a target for small-molecule inhibitors.
• Functional Modulation: Demonstrated that the MIF-2/CCL20 complex acts as a negative regulator, suppressing the individual pro-inflammatory functions of both proteins (T-cell migration and IL-6 secretion).

4. Key Results

• Screening & Binding Affinity:
  • The protein array identified CCL20, CCL24, CCL25, CCL26, CCL28, CXCL9, CXCL11, and CXCL17 as MIF-2 interactors.
  • SPR Validation: Confirmed high-affinity binding for several pairs. Notably, CCL20 showed a $K_D$ of 88.7 nM. Other high-affinity binders included CCL26 ($K_D \approx 2$ nM) and CCL28 ($K_D \approx 1.15$ nM).
• Expression in Liver Fibrosis:
  • Re-analysis of human liver RNA-seq data showed CCL20 is progressively upregulated from NAFL to NASH with advanced fibrosis (F0–F4).
  • MIF-2 is constitutively highly expressed in the liver but does not change significantly with fibrosis stage.
  • Receptor analysis showed high CD74 (MIF-2 receptor) and CXCR4 levels, while CCR6 (CCL20 receptor) remained low, suggesting CCL20 may function via non-canonical mechanisms (e.g., complex formation) in this context.
• Complex Formation & Structure:
  • MST confirmed binding ($K_D \approx 5$ $\mu$M in solution, consistent with specific interaction).
  • Peptide Array identified two CCL20 binding regions: an N-terminal $\beta$-sheet region (near the CC motif) and a C-terminal region.
  • AlphaFold 3.0 modeling predicted the CCL20 C-terminus occupies the MIF-2 tautomerase pocket.
  • Functional Validation: CCL20 significantly inhibited MIF-2's vestigial tautomerase activity, comparable to the small-molecule inhibitor 4-CPPC, confirming the structural prediction.
• In Situ Detection:
  • Western blots showed MIF-2 and CCL20 are co-expressed in human liver with a strong positive correlation ($R=0.77$).
  • PLA on human liver tissue confirmed the presence of MIF-2/CCL20 complexes in situ, with significantly higher signal frequency in fibrotic tissue compared to non-fibrotic controls.
• Functional Impact:
  • T-Cell Migration: MIF-2 induced strong CD4⁺ T-cell chemotaxis (via CXCR4). CCL20 alone had a weak effect. However, the MIF-2/CCL20 complex completely abolished chemotaxis, acting as a "stop signal."
  • Fibroblast Activation: MIF-2 and CCL20 individually induced IL-6 secretion in fibroblasts. Co-stimulation with the complex markedly suppressed IL-6 release, indicating a dampening of stromal inflammatory responses.

5. Significance

• Mechanistic Insight: The study establishes that ACKs (like MIF-2) and CKs (like CCL20) can form functional heterocomplexes that alter the biological activity of the individual components. This adds a new layer of complexity to the chemokine network in liver fibrosis.
• Therapeutic Implications: The finding that the MIF-2/CCL20 complex inhibits pro-fibrotic and pro-inflammatory signals (T-cell recruitment and IL-6 production) suggests that this interaction may be a homeostatic brake on fibrosis progression.
• Targeting Strategy: Understanding this complex formation opens new avenues for therapeutic intervention. Strategies could aim to:
  1. Disrupt the complex to unleash pro-inflammatory clearance mechanisms (if beneficial).
  2. Mimic the complex to suppress excessive inflammation and fibrosis.
  3. Target the specific interface (tautomerase pocket) to modulate MIF-2 activity.
• Broader Context: This work extends the concept of the "chemokine interactome" beyond classical chemokines to include atypical chemokines, highlighting that protein-protein interactions are crucial for fine-tuning immune responses in chronic diseases like liver fibrosis.